文献速递技术与安全腹部外周血管CT

一种血管内氧化钽基CT对比剂:模拟超重和肥胖患者体型的临床前评估

An Intravascular Tantalum Oxide-based CT Contrast Agent: Preclinical Evaluation Emulating Overweight and Obese Patient Size.
PubMed 文献 · Radiology · 2018-07-03

在四头猪的三种模拟腹围(102、119、137厘米)脂肪等效包裹模型中,比较氧化钽纳米颗粒对比剂(TaCZ)与碘普罗胺的CT成像性能。TaCZ在主动脉和肝脏的峰值强化均高于碘普罗胺,且在多数血管中血管清晰度评分更高,碘普罗胺在任何血管中均未显示更高清晰度评分。

要点

  • 在模拟超重和肥胖体型的猪模型中,TaCZ的主动脉和肝脏峰值强化均高于碘普罗胺。
  • TaCZ在102、119、137厘米腹围下分别有63%、82%、86%的血管清晰度评分高于碘普罗胺。
  • 静脉期和延迟期分别有89%和100%的静脉清晰度评分TaCZ高于碘普罗胺,无任何血管碘普罗胺评分更高。

核心结论

  • 在模拟超重和肥胖患者的猪模型中,实验性氧化钽纳米颗粒对比剂 compared with 碘普罗胺显示出更高的对比强化。

研究设计与样本

  • 临床前动物实验,四头猪,三种尺寸脂肪等效包裹模拟腹围102、119、137厘米,64排CT,静脉注射240 mg元素(Ta或I)/kg体重的TaCZ或碘普罗胺,六个扫描延迟时间点。

诊断标准与关键数值

  • 主动脉平均峰值强化:TaCZ 270 HU(σ=24.5)vs 碘普罗胺 199 HU(σ=10.2),P < .001。
  • 肝脏平均峰值强化:TaCZ 61.3 HU(σ=11.7)vs 碘普罗胺 45.2 HU(σ=8),P < .001。
  • 血管清晰度评分TaCZ高于碘普罗胺的比例:102厘米腹围63%(132/208)、119厘米腹围82%(170/208)、137厘米腹围86%(178/208),P < .01。
  • 动脉清晰度评分TaCZ高于碘普罗胺的比例:62%(208/336);静脉期静脉清晰度评分TaCZ高于碘普罗胺的比例:89%(128/144);延迟期:100%(144/144),P < .01。
  • 无任何血管显示碘普罗胺清晰度评分高于TaCZ。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To compare the CT imaging performance of a carboxybetaine zwitterionic-coated tantalum oxide (TaCZ) nanoparticle CT contrast agent with that of a conventional iodinated contrast agent in a swine model meant to simulate overweight and obese patients. Materials and Methods Four swine were evaluated inside three different-sized adipose-equivalent encasements emulating abdominal girths of 102, 119, and 137 cm. Imaging was performed with a 64-detector row CT scanner at six scan delays after intravenous injection of 240 mg element (Ta or I) per kilogram of body weight of TaCZ or iopromide. For each time point, contrast enhancement of the aorta and liver were measured by using regions of interest. Two readers independently recorded the clarity of vasculature using a five-point Likert scale. Findings were compared by using paired t tests and Wilcoxon signed-rank tests. Results Mean peak enhancement was higher for TaCZ than for iopromide in the aorta (270 HU [σ = 24.5] vs 199 HU [σ = 10.2], P < .001) and liver (61.3 HU [σ = 11.7] vs 45.2 HU [σ = 8], P < .001). Vascular clarity was higher for TaCZ than for iopromide in 63% (132 of 208), 82% (170 of 208), and 86% (178 of 208) of the individual vessels at the 102-, 119-, and 137-cm girths, respectively (P < .01). Arterial clarity scores were higher for TaCZ than for iopromide in 62% (208 of 336) of vessels. Venous clarity scores were higher for TaCZ than for iopromide in 89% (128 of 144) of the veins in the venous phase and in 100% (144 of 144) of veins in the delayed phase (P < .01). No vessel showed higher clarity score with iopromide than with TaCZ. Conclusion An experimental tantalum nanoparticle-based contrast agent showed greater contrast enhancement compared with iopromide in swine models meant to simulate overweight and obese patients. © RSNA, 2018.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lambert JW, Sun Y, Stillson C, et al. An Intravascular Tantalum Oxide-based CT Contrast Agent: Preclinical Evaluation Emulating Overweight and Obese Patient Size. Radiology. 2018. PMID: 29969071. doi:10.1148/radiol.2018172381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。